Please login to the form below

Not currently logged in
Email:
Password:

China recalls tainted leukaemia drugs

The Chinese state food and drug administration orders the recall of two contaminated leukaemia drugs which have caused adverse reactions among children

The Chinese state food and drug administration (SFDA) has ordered the recall of two contaminated leukaemia drugs which have caused adverse reactions among children.

The drugs, the majority of which were produced by a Shanghai-based pharmaceutical company have already been recovered and authorities have reportedly tracked down the remainder, according to local media reports.

The Chinese Health Ministry and the SFDA suspended production and sale of methotrexate and cytarabin, after receiving reports that several child leukaemia patients had suffered mobility impairments after treatment. The drugs had also caused urine retention among some leukaemia patients.

Both authorities said the drugs were contaminated with an anti-cancer medicine which had been added mistakenly during production and the factories manufacturing the drugs have been closed.

The new head of the new food, drug and product safety teams in China, vice-premier Wu Yi, or the "Iron Lady" as she has been dubbed, has suspended the licenses of 1,200 drug and medical equipment companies.

Wu Yi brokered the trade agreements with Russia and the US in the late 1990s, which smoothed China's entry into the World Trade Organisation in 2001.

17th September 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics